News

Number of news items returned: 141 to 160 records of 399

DSTG Therman Stress Analysis Collaboration Featured at Partnerships Week

12 July 2016

(10513 views)

"As reported earlier the Defence Science Technology Group (DSTG) have through an R&D collaboration been pursuing a development with Ocular ...

Incentives, Introductions and News - Funding Strategies Connect June July 2016

01 July 2016

(9067 views)

Dear Readers, From 1st July 2016, the Australian Government is introducing tax incentives for early stage investors. "If you invest in ...

Nifty R&D Special Offer

30 June 2016

(10867 views)

"Submit with Nifty R&D on or before 31st Aug to receive 25% off the cost of your R&D claim" Brendan White, ...

Qponics awarded $1m CRC-P Grant

30 June 2016

(10475 views)

"Queensland-based omega-3 algae farming company, Qponics, has been awarded a $1 million grant to construct a commercial-sized algae farm in ...

Freedom Suites to exhibit at Brisbane Hair and Beauty Expo

29 June 2016

(10406 views)

"Freedom Suites are pleased to announce that they will be exhibiting at the upcoming Brisbane Hair and Beauty Expo on ...

Opmantek continues strong growth and increases presence with new configuration technology

27 June 2016

(11126 views)

"Opmantek continues strong growth and increases presence in the Network Automation Market with new configuration technology" Danny Maher, Managing Director, Opmantek ...

ICS June news

24 June 2016

(10111 views)

"Certification Bodies Seek to Bridge their Skills Shortage", "Cutting Edge and Exclusive Food Security Training", "Asian Footprint in Training and ...

Squirrel & Metallum Sign Binding Heads of Agreement

17 June 2016

(11311 views)

"The Board of Metallum Limited (ASX:MNE) is pleased to announce that it has executed share sale agreements with the shareholders ...

Benojo - Latest News - June 2016

15 June 2016

(10194 views)

"As the client base grows and tech releases are almost daily Benojo is establishing itself as a philanthropic platform of ...

Ocular Robotics Releases 'RobotEye Thermal' Product Range

15 June 2016

(10154 views)

"Ocular Robotics is excited to announce the release of the RELW60 Thermal product range. This extension of the RobotEye product ...

Ocular Robotics: Successful Demonstration to US Defence

15 June 2016

(9911 views)

"The company is pleased to announce a recent successful demonstration of one of OCR’s products integrated onto a target platform ...

REHS25 Hyperspectral Sees Beyond Human Vision

15 June 2016

(9762 views)

"Of particular note in the demonstrations shown recently at the Image Sensing Show in Yokohama by OCR’s Japanese distributor ViewPLUS ...

Simultaneous Impressive Displays by OCR's Japanese Distributor ViewPLUS Inc.

15 June 2016

(9626 views)

"Ocular Robotics’ distributor in Japan, ViewPLUS Inc. had an impressive display of the company’s products at the Image Sensing Show ...

Paradigm & IODM - Offers Extended

03 June 2016

(10806 views)

"Paradigm Metals Limited is pleased to announce that it has received conditional approval from ASX to the re-quotation of its ...

Introducing Freedom Suites, Benojo, EOI's and News - Funding Strategies Connect May June 2016

30 May 2016

(10348 views)

Introducing Freedom Suites, Benojo, EOI's and News - Funding Strategies Connect May/June 2016 Dear Readers, I had a very interesting time visiting ...

ATIC reports Stellar Investment Portfolio Performance

26 May 2016

(10468 views)

 ATIC reports Stellar Investment Portfolio Performance Australian Trading and Investment Corporation Ltd reports: " Outstanding investment portfolio performance Expanded product/service offer ATIC is holding ...

Benojo - Latest news - May 2016

24 May 2016

(11102 views)

"As Benojo begins to ramp up in the Australian domestic market it attracts a globally recognised CEO, US interest, acquires ...

BlueMount Capital WA Office bolsters portfolio offering in the Food & Beverages Sector

23 May 2016

(10680 views)

BlueMount Capital WA Office bolsters portfolio offering in the Food & Beverages Sector "The Western Australian Office of BlueMount Capital is ...

Opmantek recognised as one of America's most innovative companies in the 2016 American Business Awards

23 May 2016

(10427 views)

OPMANTEK RECOGNISED AS ONE OF AMERICA’S MOST INNOVATIVE COMPANIES IN THE 2016 AMERICAN BUSINESS AWARDSSM " Opmantek has been named as one of America’s most ...

BR Sustainable Investments Australia Recommends Trac Offer

20 May 2016

(10681 views)

" Please read the prospectus documents. ASX code TRC, bookbuild code TRCXBB. We recommend the offer. The levels of CO2 in the atmosphere ...

JNCI publication involving CytImmune's CYT-21625

10 March 18

 

"JNCI publication involving CytImmune's CYT-21625"

 

"Please find attached [via the link below] an article published in the most recent version of the Journal of the National Cancer Institute (JNCI). This publication reports on a series of animal experiments comparing CytImmune's second generation nanomedicine, CYT-21625, against the commonly used chemotherapy, paclitaxel.


Key points:

1) CYT-21625 was safe with no toxicities observed.
2) The study involved three cancer models:
• Two thyroid cancers, traditional mouse xenograft models
• One Pancreatic neuroendocrine cancer, a genetically engineered mouse model.
3) Both anaplastic thyroid cancer (ATC) and pancreatic neuroendorine cancer (PNETs) are rare/orphan diseases, and have abysmal 5 year survival rates -- less than 5% for ATC and 16% for PNET patients with advanced disease.
4) CYT-21625 out-performed paclitaxel as measured by overall survival and using biological indicators that were specific to each cancer and model used.
We believe this study confirms the potential of the the Aurimune platform to deliver existing cancer drugs more effectively and with fewer toxic side effects. The paper concludes:

"CYT-21625 is effective in mice with PNETs [Pancreatic NeuroEndocrine Tumors] and metastatic human thyroid cancer with no toxicities. Thus, CYT-21625 should be studied in patients with advanced PNETs and thyroid cancer."

*Note that this study also used a CYT-6091 monotherapy as a control. As expected in this setting, while CYT-6091 showed some limited efficacy, it was inferior to therapies in which TNF is delivered in combination with chemotherapy. "

 

David Oarr, Chief Communications Officer, Project Karkinos, 10 March 2018.

Additional Documents

JNCI_CYT21625